RAP1A and chronic myelogenous leukemia, BCR-ABL1 positive: Bone-marrow and splenocyte cells harvested from mice treated with CML-07–119 displayed significantly higher concentration of unprenylated RAP1A as compared to the controls, demonstrating the expected biochemical outcome of in vivo GGPPS inhibition.